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Guidelines on diagnostics and therapy of Fabry disease
have already been compiled in a number of European
countries and are being prepared in others. A synthesis of
these national guidelines seems to be a sensible option for
preparing a prospective European consensus document in
the not too distant future. While clinical diagnostics is
extensively discussed in the various guidelines, at present
there is no consensus on laboratory diagnostic tests for
Fabry disease either at national level or at the level of the
European Union. There is a widespread variation
concerning the diagnostic value of the various methods,
such as enzyme activity testing, gene analysis, biopsies,
Gb3 measurement etc. and on what should be used and how
they compare, if indeed they do. This results in lack of
agreement regarding the clinical pathology of the condition.
While experts throughout Europe agree on many aspects
of the laboratory diagnosis of Fabry disease (for a recent
review see Winchester and Young 2010), there are some
specific issues which need further discussion before a
general recommendation can be made. In order to promote
this process, three one-and-a-half day ad hoc meetings* of
European experts** were organized in 2009 with the aim of
defining a consensus on laboratory diagnostics of Fabry
disease that should allow for laboratories performing this
diagnostic service to work to the same standards. Invita-
tions to attend the meetings were based on, in addition to
geographic considerations, outstanding scientific accom-
plishments in the field and/or active involvement in the
laboratory diagnostics of Fabry disease.
*‘Diagnostic use and value of Gb3 and lysoGb3 in Fabry
disease’ (April 22-23, 2009, Bad Nauheim, Germany); ‘Diag-
nostic use and value of measuring alpha-galactosidase A activity
in Fabry disease’ (July 16-17, 2009, Berlin, Germany);
‘Diagnostic use and value of mutations of the GLA gene in
Fabry disease’ (November 3-4, 2009, Barcelona, Spain).
**J.M.F.G. Aerts (Amsterdam, The Netherlands), M. Beck
(Mainz, Germany), O. Bodamer (Salzburg, Austria), A.
Cooper (Manchester, United Kingdom), A. Gal (Hamburg,
Germany), D. Germain (Paris, France), R. Giugliani (Zürich,
Switzerland), D. Hughes (London, United Kingdom), L.
Kuchar (Prague, Czech Republic), J. Ledvinova (Prague,
Czech Republic), Z. Lukacs (Hamburg, Germany), C.
Navarro (Vigo, Spain), E. Paschke (Graz, Austria), M. Piraud
(Lyon, France), A. Rolfs (Rostock, Germany), C. Sa Miranda
(Porto, Portugal), M. van Slegtenhorst (Rotterdam, The
Netherlands), H. Treslova (Prague, Czech Republic), M.T.
Vanier (Lyon, France), F.W. Verheijen (Rotterdam, The
Netherlands), B. Winchester (London, United Kingdom).
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Primary objectives of the initiative were (i) establish-
ment of ‘gold standards’ and practical algorithms for
diagnosis of Fabry disease, (ii) promotion of a concept of
certification/accreditation for diagnostic and treatment
centres of excellence, and (iii) provision of a platform for
future treatment guidelines. In particular, three specific
issues were selected by the organizers: the diagnostic utility
of measurement of Gb3 and lysoGb3, evaluation of α-
galactosidase A activity, and analysing mutations of the
GLA gene in patients with Fabry disease. The most
important goal of these workshops was to provide a
platform for the experts to exchange ideas and experiences
and share experimental data with each other, even if
preliminary or yet unpublished, on the use, practical value,
and significance of different laboratory approaches in the
diagnostics of Fabry disease. All data were critically discussed
by the panel and used to prepare this recommendation for the
medical community. We hope that this document will serve as
a starting point for further discussion that, in the end, should
result in a consensus, provide essential guidance to physicians,
and ensure a better differential and timely diagnosis of
patients with Fabry disease.
Diagnostic use and value of measuring α-galactosidase
A activity
In normal human tissues, there are two lysosomal glyco-
sidases with α-galactosidase activity towards synthetic
substrates. α-Galactosidase A (α-GAL; EC 3.2.1.22)
which is deficient in Fabry disease, acts on terminal α-
galactosyl residues in glycosphingolipids, whereas the so
called α-galactosidase B is an α-N-acetylgalactosaminidase
(α-NAGAL; EC 3.2.1.49) that acts on natural substrates
with terminal α-N-acetylgalactosaminyl residues and is
defective in Schindler disease. α-Galactosidase A does
not catalyse the hydrolysis of the natural substrates of α-
NAGAL whereas α-NAGAL may act on some natural
substrates with terminal α-galactosyl residues (Clark and
Garman 2009). As both enzymes act on synthetic α-
galactoside substrates, α-N-acetylgalactosamine, a specific
inhibitor of α-NAGAL is added to assays of α-galactosidase
A activity for the diagnosis of Fabry disease. The genes
(GLA and NAGA) encoding α-GAL and α-NAGAL are on
chromosomes Xq22.1 and 22q13, respectively. Although the
two genes show considerable homology, as they evolved
from a common ancestral precursor (Clark and Garman
2009), α-galactosidase A and α-NAGAL have distinct
physicochemical properties, and antibodies raised against
one do not cross-react with the other.
α-Galactosidase A is a typical lysosomal hydrolase with
optimal activity towards natural and synthetic substrates at
pH 3.8–4.6. It is a glycoprotein and is transported to the
lysosomes via the mannose-6-phosphate pathway. It is
synthesized as a precursor of 50 kDa and is processed to
a mature lysosomal form of 46 kDa by partial proteolysis
and modification of its carbohydrates. The enzyme is a
homodimer with an active site in each of the monomers.
Hydrolysis of its natural substrates in vivo requires saposin
B whereas that in vitro requires the addition of a detergent,
usually sodium taurocholate. Patients with a genetic
deficiency of saposin B also accumulate the substrates for
α-galactosidase A, as in Fabry disease. The three-
dimensional structure of recombinant human α-
galactosidase A has been determined by X-ray crystallog-
raphy at a resolution of 3.25Å, and used to understand the
effects of mutations on the structure and function of the
enzyme (Garman and Garboczi 2004, Garman 2007).
After thorough clinical evaluation, determination of α-
galactosidase A activity is the first step in the laboratory
diagnosis of a patient suspected of having Fabry disease,
unless there is a known familial GLA mutation, for which
DNA analysis is straightforward (see later). The activity can
be determined in various materials, such as plasma,
leukocytes, fibroblasts, or dried blood spots (DBS); the
assay is rapid, reliable, and cost-effective. Currently the
assay of α-galactosidase A activity in leukocytes represents
the diagnostic ‘gold-standard’. A skin biopsy is rarely taken
for initial diagnosis but studies on fibroblasts could be
useful for molecular characterization of the enzyme
deficiency. The most commonly used method of enzyme
analysis is based upon cleavage of 4-methylumbelliferyl-α-
D-galactoside, a synthetic fluorigenic substrate. Recently a
substrate suitable to assay enzyme activity by electrospray
ionization/tandem mass spectrometry (ESI/TMS) has also
become available (Li et al. 2004, Zhang et al. 2010). The
activity of α-galactosidase A should always be determined
in the presence of α-N-acetylgalactosamine, which inhibits
α-galactosidase B. In addition, another lysosomal enzyme,
preferably β-galactosidase, should always be assayed to
evaluate sample quality. As enzyme activity may diminish
rapidly if the sample is inappropriately stored and/or
transported, the diagnostic laboratory should be contacted
in advance for information regarding appropriate sample
storage and shipping conditions. About 2% of the popula-
tion/Fabry patients carry the non-synonymous change c.937
G>T (p.Asp313Tyr). This variant has low α-galactosidase A
activity in plasma compared to the wild-type and about 60%
of the mean α-galactosidase A activity of the wild-type in
cells. The p.Asp313Tyr variant is stable at lysosomal pH and
is not disease-causing (pseudodeficiency).
Males with the classic Fabry disease phenotype can be
reliably diagnosed by detecting complete deficiency or
only negligible (<5% of mean normal) α-galactosidase A
activity. Single male patients with attenuated phenotypes
may show considerable residual enzyme activities (e.g.
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Gaspar et al. 2010) that are still, however, well below the
normal reference range. If initial enzyme activity analysis
is performed on DBS of a male proband and shows
pathologic values, a confirmatory assay, preferably on
leukocytes, is recommended. For the index patient of any
family with a biochemically proven α-galactosidase A
deficiency, mutation analysis of the GLA gene should be
offered. This test can confirm the diagnosis and may
provide additional information for disease prognosis and
therapy. It is essential when genetic counselling of family
members is desired (see later).
Identification of heterozygous females is not reliably
made by the measurements of α-galactosidase A activity
because of the significant levels of activity that may be
present in these samples due to random X-inactivation.
Thus for females, a number of complementary diagnostic
approaches is used currently, including measurement of
urinary/plasma storage products, and histology/electron
microscopy. However, only the identification of a disease-
relevant heterozygous GLA mutation allows definite diag-
nosis of carrier status.
Neonatal screening for Fabry disease in males is
technically feasible by measurement of α-galactosidase A
activity in DBS using either the fluorigenic or mass
spectrometric substrate and will detect cases both with
complete deficiency and residual enzyme activity (Lin et al.
2009). High-throughput measurement of α-galactosidase A
activity in leukocytes and DBS, for example by the
technique of ESI/TMS, has been used to identify patients
with Fabry disease in cohorts with advanced organ
manifestations typical for Fabry disease (high-risk popula-
tions; for a recent review see Linthorst et al. 2010). It has
been reported that β-glucuronidase activity is elevated in
Fabry patients (Z. Lukacs, personal communication).
Therefore the ratio of α-galactosidase A to β-
glucuronidase activities may be helpful for increasing
diagnostic discrimination, particularly for heterozygotes in
these populations.
Diagnostic use and value of Gb3 and lysoGb3
Gb3 (Gb3Cer, globotriaosylceramide), also known as GL3
or CTH, is a substrate of α-galactosidase A and the main
glycosphingolipid which accumulates when there is a
deficiency of the enzyme. It may therefore be useful in
diagnosis and assessment of disease burden. Deacylated
Gb3, globotriaosylsphingosine (lysoGb3Cer or lysoGb3), is
a minor metabolite recently identified in plasma of patients
with Fabry disease. LysoGb3 might be more directly
involved in the pathology and may also be useful in
monitoring the disease (Aerts et al. 2008). Gb3 profiling
(comparative analysis of various Gb3 isoforms) rather than
measurement of the total urinary Gb3 concentrations, may
represent a new diagnostic avenue in the future.
For biochemical analysis, Gb3 is easily accessible in
various body fluids, including plasma and urine, and there
are a number of validated assays including HPLC, TLC and
LC/MS. In general, Gb3 should be measured in urine rather
than in plasma, whereas lysoGb3 should be determined in
plasma (Young et al. 2005, Togawa et al. 2010). Samples
need to be sent fresh to the laboratory or should be frozen
and subsequently transported frozen. It is recommended
that both the biochemical analysis of lysoGb3 and Gb3 in
plasma and urine, respectively, as well as the metabolite
analysis are performed in specialized centers with appro-
priate experience. Gb3 inclusions can also be detected in
cells of various tissues and organs, e.g. by biopsy of the
conjunctiva, skin, kidney or heart, by electron microscopy
and histochemistry including immunohistochemistry.
Plasma Gb3 levels do not correlate with disease
manifestations: They are elevated in males with Fabry
disease but are normal or only mildly elevated in females.
Since Gb3 seems to be directly involved in the renal
pathology of Fabry disease as a result of vascular
compromise, podocyte toxicity, and focal tubular damage
and sclerosis, quantification of urinary Gb3, that is derived
primarily from tubular epithelial cells, is a possible
diagnostic procedure for patients presenting with the classic
Fabry disease phenotype (Sessa et al. 2003). A relationship
between urinary Gb3 levels and Fabry disease severity as
well as to therapeutic response has been demonstrated in a
few studies (Whitfield et al. 2005, Banikazemi et al. 2007,
Eng et al. 2001, Schiffmann et al. 2001). More recent
studies suggest that there is no linear relationship between
urinary Gb3 concentrations and end-organ effects of Fabry
disease in male or in female patients. Furthermore it is
currently unclear whether or not increased urinary Gb3
concentration can be taken as a specific marker for disease-
related lysosomal storage. Whilst there is no doubt that Gb3
accumulates in patients with Fabry disease, from placental
development onwards (Vedder et al. 2006), its role in the
assessment or management of patients with this condition is
contentious.
While single assessments of Gb3 add only very little to
the diagnosis of patients with biochemically and/or clini-
cally ascertained Fabry disease, serial measurements of
total urinary Gb3 (plasma lysoGb3) in the same individual
may be used to monitor the progression of the pathological
process. In male patients, a response to ERT is indicated by
a decline of urinary Gb3, whereas an increase after
prolonged enzyme administration may point to the exis-
tence of interfering antibodies against infused α-
galactosidase A (Schiffmann et al. 2006, Vedder et al.
2007, Hughes et al. 2008). Analysis of total urinary Gb3
from a 12-24 h urine sample may be a diagnostic adjunct in
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females suspected of having Fabry disease when no male
index patient is available for mutation analysis.
In symptomatic males with Fabry disease, plasma
lysoGb3 is elevated probably from an early age, and is
strikingly high in adult male patients, although no
correlation has been found between plasma lysoGb3
and disease manifestations (Aerts et al. 2008). In females,
plasma lysoGb3 levels increase steadily and show a weak
correlation with disease manifestation. Provided that
comprehensive analyses of plasma lysoGb3 data from
large cohorts of patients with Fabry disease confirm the
preliminary observations, lysoGb3 may prove to be a
promising novel diagnostic tool (Rombach et al. 2010).
Where gene alterations are found with unclear functional
or pathological implications in females, the assessment of
Gb3 metabolites/isoforms (urinary Gb3 and plasma
lysoGb3) is recommended.
Diagnostic use and value of mutations of the GLA gene
The GLA gene, encoding α-galactosidase A, contains seven
exons ranging from 92 to 291 base pairs (bp) in length. The
coding region consists of 1,290 bp and encodes a
polypeptide of 429 amino acids, with the first 31 residues
representing a signal sequence. As of 30th of June 2009, a
total of 599 GLA sequence changes, including 435 probable
pathogenic point mutations (missense, nonsense, and splice
site) and 150 disease-causing ‘short length’ rearrangements
(mainly deletions and duplications affecting less than 65
nucleotides) as well as 14 DNA polymorphisms have been
reported (for a recent review see Gal 2010). Large
rearrangements involving one or more exons or the whole
GLA gene seem to be infrequent (ca. 5%) in patients with
Fabry disease. Most of the GLA mutations found in patients
with Fabry disease are novel (unique, ‘private’). The
frequency of de novo mutations has been estimated to be
3-10%. There are a few reports of patients carrying two
different, highly probable disease-causing GLA mutations
on the same allele. In contrast, patients may carry one or
more of the common GLA polymorphisms, including
several non-synonymous changes, or rare non-pathogenic
variants, in addition to their disease-causing mutation. To
date, no experimentally validated data have been presented
that any of these latter sequence variants, alone or in
combination, are disease-causing.
As a practical approach one can define two classes of
mutations to assess their pathogenic significance. Class 1
mutations are predicted to have high probability of causing
disease because they create a premature stop codon
(nonsense or frame-shift mutations) with the consequent
loss of the protein, affect the evolutionarily conserved
splice-site dinucleotides at the beginning or the end of one
of the 6 GLA introns and interfere with the proper splicing
of the GLA mRNA, or severely disrupt the coding sequence
by a large rearrangement. Sequence changes resulting in a
catalytically inactive (non-functional) enzyme, for example
missense mutations affecting one of the 15 residues in the
enzyme active site, or one of the 8 cysteines essential for
proper three-dimensional protein folding, are also class 1
1
Laboratory Diagnostics 
in Fabry Disease: Males
Clinical suspicion of Fabry disease




Attenuated form of 
Fabry disease2















in Fabry Disease: Females
Clinical suspicion of Fabry disease
Measure α-galactosidase A




Disease-causing mutation4 No disease-causing mutation6




Fig. 1 Algorithm for the laboratory diagnosis of (a) male and (b)
female patients with Fabry disease. The flow charts represent
summaries of the discussion and conclusions in the text, with extra
clarification in points 1-6. 1) Demonstration of a deficiency of α-
galactosidase A in leukocytes and plasma from the same blood sample
is supporting evidence for a diagnosis of Fabry disease. 2) Variants of
Fabry disease with residual α-galactosidase A activity. 3) A patient
with some symptoms of Fabry disease not due to deficiency of α-
galactosidase A. 4) Class 1 mutation and mutations previously found
in affected male or female Fabry patients. 5) Low α-galactosidase A
activity can be suggestive of carrier status but not definitive. 6) To
decide whether the proband has Fabry disease, all or some of the
following investigations should be carried out: (a) re-evaluation of
clinical presentation, (b) analysis of family pedigree, (c) measurement
of urinary Gb3, and (d) in absence of a Class 1 mutation, any
sequence change detected in the GLA gene must be expressed in vitro
to investigate its effect on activity and/or structure of enzyme
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mutations. Finally, recurrent disease-causing mutations
and the growing number of GLA mutations that have been
shown to result in non-functional enzyme in in vitro
expression studies in cells in cultures transduced with the
relevant mutant cDNA also belong to this group. It has
been suggested that the pathology of some ‘simple’
disease-causing mutations might occasionally be complex.
Indeed, some DNA changes thought to be missense
mutations (e.g. p.Ser65Thr, p.Gly183Ser, p.Lys213Asn,
or p.Met267Ile) seem to interfere with normal splicing of
the GLA mRNA (Lai et al. 2003). Similarly, two deep
intronic point mutations (c.639+861C>T and c.639+919
G>A) apparently result in α-galactosidase A deficiency
by causing complex changes in the pattern of splicing
(Ishii et al. 2002, Filoni et al. 2008). About 50% of males
with enzymatically proven Fabry disease carry a Class 1
mutation.
Mutations that have been found in males with normal α-
galactosidase A activities or with somewhat decreased
enzyme activities, which are still, however, well above the
pathologic range of values, are called Class 2 mutations and
are almost certainly non-pathogenic. These include poly-
morphisms or sequence changes, e.g. c.937G>T
(p.D313Y) described as pseudodeficiency alleles.
Routine mutation analysis of the GLA gene consists of
sequencing of the coding region and exon-intron bound-
aries. The interpretation of gene alterations should be
performed by an expert and genetic counselling should be
offered. In more than 97% of males with pathologic α-
galactosidase A activities, a sequence variant (Class 1
mutations or yet unclassified sequence changes) can be
detected by routine mutation analysis. The identification
of Class 1 mutations is considered a very useful and
independent confirmation of the biochemical (and clinical)
diagnosis. A small number of mutations, in particular
exon-spanning duplications or inversions and deep
intronic mutations, may escape detection by using the
above method and can only be identified by more
sophisticated procedures, such as the analysis of the
mRNA or MLPA (multiplex ligation-dependent probe
amplification). However, even if no highly probable
disease-causing mutation is found in a male patient with
an α-galactosidase A deficiency, the diagnosis of Fabry
disease remains valid. For mutations not categorized as
Class 1 or Class 2, a thorough clinical, biochemical and
genetic analysis of the patient and his family may allow
designation of the mutation as disease-causing or not.
Analysis of evolutionary conservation of the relevant
sequence and its absence in a large cohort of unaffected
individuals may provide additional arguments for a
pathogenic relevance of a change. An easily accessible
and quality-controlled gene-specific mutation database
would be an invaluable tool both for physicians treating
patients, genetic counselors, and scientists involved in
DNA diagnostics or research.
Both Class 1 and Class 2 mutations also occur in
females. Since enzyme activity measurements do not
reliably detect heterozygotes, and many of the clinical
features of Fabry disease are frequently observed in the
general population, DNA diagnostics is much less efficient
in identifying heterozygotes among women with clinical
suspicion for Fabry disease than in confirming diagnosis in
males with enzymatically proven Fabry disease. Carriers in
families with Fabry disease can be identified by pedigree
analysis and/or by showing that they have inherited the
family-specific mutation. If bidirectional sequencing of the
coding region and exon-intron boundaries do not reveal
heterozygosity for a Class 1 mutation in a female DNA
sample, MLPA may help to pick up the few cases of large
DNA rearrangements in females, whereas the analysis of
mRNA may be complicated by nonsense-mediated decay. In
addition, a thorough clinical re-evaluation of the patient and
additional biochemical tests are recommended. A careful
analysis of the pedigree by a genetic counselor should also be
offered, keeping in mind that nine out of ten patients with
Fabry disease should have a positive family history for the
trait. In females with typical signs and symptoms of Fabry
disease but without positive family history, only the identifi-
cation of a disease-relevant heterozygous GLA mutation
allows definite diagnosis of carrier status.
Conclusions (Fig. 1): (i) Thorough analysis of the patient’s
family and medical history together with a clinical examina-
tion are essential prior to laboratory testing. (ii) Diagnostic
tests should be done in laboratories with appropriate quality
control schemes, experience, and sample load. (iii) Analysis
of α-galactosidase A activity is the standard diagnostic test of
Fabry disease in males. Molecular analysis of the GLA gene
is necessary to diagnose heterozygotes.
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